Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Seattle Genetics to receive $20M after GlaxoSmithKline Blenrep gets FDA approval » 08:22
08/06/20
08/06
08:22
08/06/20
08:22
SGEN

Seattle Genetics

$162.51 /

-2.33 (-1.41%)

, GSK

GlaxoSmithKline

$41.21 /

-0.05 (-0.12%)

Seattle Genetic (SGEN)…

Seattle Genetic (SGEN) announced FDA, approval of GlaxoSmithKline's (GSK) Blenrep, an antibody-drug conjugate targeting B-cell maturation antigen that utilizes Seattle Genetics' proprietary technology. Blenrep was developed and will be commercialized by GSK. The approval triggers a $20M milestone payment and entitles Seattle Genetics to royalties on Blenrep product sales. Blenrep was approved for the treatment of patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.

ShowHide Related Items >><<
SGEN Seattle Genetics
$162.51 /

-2.33 (-1.41%)

GSK GlaxoSmithKline
$41.21 /

-0.05 (-0.12%)

SGEN Seattle Genetics
$162.51 /

-2.33 (-1.41%)

07/31/20 H.C. Wainwright
Seattle Genetics price target raised to $200 from $175 at H.C. Wainwright
07/24/20 Piper Sandler
Seattle Genetics downgraded to Neutral from Overweight at Piper Sandler
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
GSK GlaxoSmithKline
$41.21 /

-0.05 (-0.12%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
SGEN Seattle Genetics
$162.51 /

-2.33 (-1.41%)

GSK GlaxoSmithKline
$41.21 /

-0.05 (-0.12%)

GSK GlaxoSmithKline
$41.21 /

-0.05 (-0.12%)

SGEN Seattle Genetics
$162.51 /

-2.33 (-1.41%)

GSK GlaxoSmithKline
$41.21 /

-0.05 (-0.12%)

GSK GlaxoSmithKline
$41.21 /

-0.05 (-0.12%)

Over a week ago
Recommendations
Seattle Genetics price target raised to $200 from $175 at H.C. Wainwright » 06:16
07/31/20
07/31
06:16
07/31/20
06:16
SGEN

Seattle Genetics

$171.04 /

+2.62 (+1.56%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Seattle Genetics to $200 from $175 and reiterates a Buy rating on the shares. The analyst believes Tukysa's "differentiating value propositions are highly translatable in different cancers."

ShowHide Related Items >><<
SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

07/24/20 Piper Sandler
Seattle Genetics downgraded to Neutral from Overweight at Piper Sandler
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

On The Fly
Fly Intel: After-Hours Movers » 19:09
07/30/20
07/30
19:09
07/30/20
19:09
MDRX

Allscripts

$7.60 /

+0.175 (+2.36%)

, HURN

Huron

$44.15 /

+0.32 (+0.73%)

, BRKS

Brooks Automation

$47.22 /

+1.16 (+2.52%)

, BZH

Beazer Homes

$11.29 /

-0.095 (-0.83%)

, WWE

WWE

$45.45 /

+0.85 (+1.91%)

, FB

Facebook

$234.63 /

+1.31 (+0.56%)

, ATUS

Altice USA

$25.09 /

-0.135 (-0.54%)

, CVA

Covanta

$9.53 /

-0.13 (-1.35%)

, AAPL

Apple

$385.14 /

+4.91 (+1.29%)

, BAND

Bandwidth

$148.70 /

+1.51 (+1.03%)

, FLEX

Flex

$11.64 /

+0.575 (+5.20%)

, AMZN

Amazon.com

$3,050.97 /

+17.7 (+0.58%)

, VRTU

Virtusa

$35.18 /

+0.4 (+1.15%)

, BLDR

Builders FirstSource

$23.38 /

-0.33 (-1.39%)

, LOCO

El Pollo Loco

$17.21 /

+0.17 (+1.00%)

, RP

RealPage

$62.86 /

-0.26 (-0.41%)

, FLS

Flowserve

$29.93 /

-0.51 (-1.68%)

, MX

MagnaChip

$11.33 /

+0.4 (+3.66%)

, F

Ford

$6.74 /

-0.18 (-2.60%)

, KNSL

Kinsale Capital Group

$166.09 /

-0.84 (-0.50%)

, HIGH

Highland Financial

$0.00 /

+ (+0.00%)

, OPK

Opko Health

$5.91 /

+0.12 (+2.07%)

, TEAM

Atlassian

$188.01 /

+0.86 (+0.46%)

, CASA

Casa Systems

$5.69 /

+0.89 (+18.54%)

, WRTC

Wrap Technologies

$11.54 /

+0.3 (+2.67%)

, RDFN

Redfin

$42.94 /

+1.4 (+3.37%)

, TWOU

2U

$43.89 /

+0.62 (+1.43%)

, SHAK

Shake Shack

$55.47 /

+0.63 (+1.15%)

, MOH

Molina Healthcare

$188.74 /

+0.905 (+0.48%)

, EGHT

8x8, Inc.

$17.11 /

+0.01 (+0.06%)

, POWI

Power Integrations

$125.97 /

+2.84 (+2.31%)

, EXPE

Expedia

$84.94 /

-0.36 (-0.42%)

, XPO

XPO Logistics

$86.59 /

+2.475 (+2.94%)

, GILD

Gilead

$72.30 /

-0.74 (-1.01%)

, FORM

FormFactor

$30.87 /

+0.78 (+2.59%)

, XLNX

Xilinx

$111.94 /

+4.06 (+3.76%)

, MITK

Mitek Systems

$10.82 /

+0.83 (+8.31%)

, NVST

Envista

$22.59 /

-0.15 (-0.66%)

, ZEN

Zendesk

$100.46 /

+1.16 (+1.17%)

, TDW

Tidewater

$6.17 /

-0.21 (-3.29%)

, SGEN

Seattle Genetics

$171.04 /

+2.62 (+1.56%)

, FND

Floor & Decor

$70.00 /

-0.57 (-0.81%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
ZEN Zendesk
$100.46 /

+1.16 (+1.17%)

XPO XPO Logistics
$86.59 /

+2.475 (+2.94%)

XLNX Xilinx
$111.94 /

+4.06 (+3.76%)

WWE WWE
$45.45 /

+0.85 (+1.91%)

WRTC Wrap Technologies
$11.54 /

+0.3 (+2.67%)

VRTU Virtusa
$35.18 /

+0.4 (+1.15%)

TWOU 2U
$43.89 /

+0.62 (+1.43%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

RP RealPage
$62.86 /

-0.26 (-0.41%)

RDFN Redfin
$42.94 /

+1.4 (+3.37%)

POWI Power Integrations
$125.97 /

+2.84 (+2.31%)

OPK Opko Health
$5.91 /

+0.12 (+2.07%)

NVST Envista
$22.59 /

-0.15 (-0.66%)

MX MagnaChip
$11.33 /

+0.4 (+3.66%)

MOH Molina Healthcare
$188.74 /

+0.905 (+0.48%)

MITK Mitek Systems
$10.82 /

+0.83 (+8.31%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

LOCO El Pollo Loco
$17.21 /

+0.17 (+1.00%)

HURN Huron
$44.15 /

+0.32 (+0.73%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FORM FormFactor
$30.87 /

+0.78 (+2.59%)

FND Floor & Decor
$70.00 /

-0.57 (-0.81%)

FLS Flowserve
$29.93 /

-0.51 (-1.68%)

FLEX Flex
$11.64 /

+0.575 (+5.20%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

F Ford
$6.74 /

-0.18 (-2.60%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

EGHT 8x8, Inc.
$17.11 /

+0.01 (+0.06%)

CVA Covanta
$9.53 /

-0.13 (-1.35%)

CASA Casa Systems
$5.69 /

+0.89 (+18.54%)

BZH Beazer Homes
$11.29 /

-0.095 (-0.83%)

BRKS Brooks Automation
$47.22 /

+1.16 (+2.52%)

BLDR Builders FirstSource
$23.38 /

-0.33 (-1.39%)

BAND Bandwidth
$148.70 /

+1.51 (+1.03%)

ATUS Altice USA
$25.09 /

-0.135 (-0.54%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

07/21/20 Goldman Sachs
Allscripts downgraded to Sell from Neutral at Goldman Sachs
06/11/20 Deutsche Bank
Allscripts price target lowered to $9 from $11 at Deutsche Bank
04/22/20 Jefferies
Allscripts downgraded to Hold due to pressure on customers at Jefferies
04/22/20 Jefferies
Allscripts downgraded to Hold from Buy at Jefferies
HURN Huron
$44.15 /

+0.32 (+0.73%)

05/01/20 Benchmark
Huron downgraded to Hold on limited visibility at Benchmark
05/01/20 Benchmark
Huron downgraded to Hold from Buy at Benchmark
01/06/20 Truist
Huron price target raised to $80 from $74 at SunTrust
10/31/19 Barrington
Huron price target raised to $76 from $68 at Barrington
BRKS Brooks Automation
$47.22 /

+1.16 (+2.52%)

06/29/20 B. Riley FBR
Brooks Automation price target raised to $55 from $50 at B. Riley FBR
06/22/20 Stifel
Brooks Automation downgraded to Hold from Buy at Stifel
04/09/20 Needham
Brooks Automation initiated with a Hold at Needham
12/02/19 Citi
Brooks Automation likely to trade down on 10-K delay, says Citi
BZH Beazer Homes
$11.29 /

-0.095 (-0.83%)

04/07/20 Wedbush
Beazer Homes price target lowered to $8 from $16 at Wedbush
01/31/20 Wedbush
Wedbush doesn't see new catalyst emerging for Beazer Homes shares
01/31/20 Wedbush
Beazer Homes downgraded to Neutral from Outperform at Wedbush
12/27/19 Wedbush
Lower homes supply should support homebuilder pricing power, says Wedbush
WWE WWE
$45.45 /

+0.85 (+1.91%)

07/10/20 Loop Capital
WWE price target raised to $37 from $30 at Loop Capital
06/23/20 Needham
WWE price target raised to $50 from $45 at Needham
06/02/20 MKM Partners
WWE Network's free version a 'step forward', says MKM Partners
04/24/20 Wells Fargo
Wells Fargo 'worried, not excited' about WWE
FB Facebook
$234.63 /

+1.31 (+0.56%)

07/28/20 Deutsche Bank
Facebook price target raised to $275 from $220 at Deutsche Bank
07/28/20 Mizuho
Facebook price target raised to $270 from $245 at Mizuho
07/27/20 Stifel
Stifel sees strong user and engagement metrics, cautious outlook from Facebook
07/27/20 Wedbush
Facebook Q2 audience upside to be tempered by weaker ad backdrop, says Wedbush
ATUS Altice USA
$25.09 /

-0.135 (-0.54%)

07/15/20 HSBC
Altice USA upgraded to Buy from Hold at HSBC
06/26/20 Nomura Instinet
Comcast 'green shoots' are emerging, says Nomura Instinet
05/05/20 Bernstein
Altice USA downgraded to Market Perform on poor execution at Bernstein
05/05/20 Bernstein
Altice USA downgraded to Market Perform from Outperform at Bernstein
CVA Covanta
$9.53 /

-0.13 (-1.35%)

05/13/20 UBS
Covanta upgraded to Buy from Neutral at UBS
05/10/20 Stifel
Covanta upgraded to Hold from Sell at Stifel
04/15/20
Fly Intel: Top five analyst downgrades
04/15/20 Stifel
Covanta downgraded to Sell from Buy at Stifel
AAPL Apple
$385.14 /

+4.91 (+1.29%)

07/30/20 Berenberg
Activision Blizzard price target raised to $88 from $83 at Berenberg
07/29/20 Credit Suisse
Apple price target raised to $340 from $295 at Credit Suisse
07/28/20 Wedbush
All eyes on Apple's iPhone 12 launch into the Fall, says Wedbush
07/28/20 Deutsche Bank
Deutsche Bank sees 'high bar' into upcoming Apple results
BAND Bandwidth
$148.70 /

+1.51 (+1.03%)

07/24/20 Canaccord
Bandwidth price target raised to $157 from $130 at Canaccord
05/29/20 Canaccord
Bandwidth assumed with a Buy at Canaccord
05/11/20
Fly Intel: Top five analyst initiations
05/11/20 William Blair
Bandwidth initiated with an Outperform at William Blair
FLEX Flex
$11.64 /

+0.575 (+5.20%)

04/22/20 RBC Capital
Flex initiated with a Sector Perform at RBC Capital
03/11/20 JPMorgan
JPMorgan downgrades TTM Technologies to Neutral, prefers others in space
03/10/20 Citi
Flex price target lowered to $13 from $16 at Citi
02/24/20 Stifel
Stifel expects Amphenol peers to follow company in warning due to coronavirus
AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

07/30/20 MKM Partners
United Natural Foods initiated with a Buy at MKM Partners
07/30/20 BMO Capital
Amazon.com price target raised to $3,500 from $2,850 at BMO Capital
07/28/20 Jefferies
Amazon.com set to deliver on high expectations, says Jefferies
07/27/20 Wells Fargo
Amazon.com price target raised to $3,600 from $3,000 at Wells Fargo
VRTU Virtusa
$35.18 /

+0.4 (+1.15%)

05/14/20 William Blair
Virtusa downgraded to Market Perform from Outperform at William Blair
02/07/20 Needham
Virtusa price target raised to $56 from $48 at Needham
01/07/20 Barrington
Adtalem, Tivity, Virtusa among Barrington's Best Ideas for 2020
01/06/20 Wedbush
Wedbush says buy Virtusa on weakness as market 'overreacts' to Citi renewal
BLDR Builders FirstSource
$23.38 /

-0.33 (-1.39%)

07/16/20 BTIG
Installed Building Products, Builders FirstSource price targets raised at BTIG
07/15/20 B. Riley FBR
Builders FirstSource price target raised to $19 from $14 at B. Riley FBR
07/08/20 Truist
SunTrust ups Installed Building Products, TopBuild, Builders FirstSource targets
06/05/20 Evercore ISI
Builders FirstSource downgraded to In Line from Outperform at Evercore ISI
LOCO El Pollo Loco
$17.21 /

+0.17 (+1.00%)

04/20/20 CL King
El Pollo Loco initiated with a Buy at CL King
04/01/20 Truist
El Pollo Loco upgraded to Buy from Hold at SunTrust
04/01/20 Truist
El Pollo Loco upgraded to Buy from Hold at SunTrust
11/01/19 Truist
El Pollo Loco price target raised to $14 from $11 at SunTrust
RP RealPage
$62.86 /

-0.26 (-0.41%)

07/17/20 RBC Capital
RealPage price target raised to $74 from $66 at RBC Capital
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Wells Fargo
RealPage initiated with an Overweight at Wells Fargo
06/23/20 BMO Capital
RealPage initiated with an Outperform at BMO Capital
FLS Flowserve
$29.93 /

-0.51 (-1.68%)

07/06/20
Fly Intel: Top five analyst downgrades
07/06/20 Cowen
Flowserve downgraded to Market Perform from Outperform at Cowen
06/30/20 Citi
Flowserve selloff brings opportunity for long-term investors, says Citi
05/22/20
Fly Intel: Top five analyst upgrades
MX MagnaChip
$11.33 /

+0.4 (+3.66%)

F Ford
$6.74 /

-0.18 (-2.60%)

07/24/20 Barclays
Ford price target raised to $7 from $4 at Barclays
07/15/20 Jefferies
Jefferies says Fox Factory absence on Bronco doesn't impair competitive position
07/14/20 Baird
Fox Factory down on Ford picking Bilstein for Bronco shocks, says Baird
06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
KNSL Kinsale Capital Group
$166.09 /

-0.84 (-0.50%)

02/24/20 Truist
Kinsale Capital Group price target raised to $140 from $110 at SunTrust
11/26/19 Truist
Kinsale Capital Group price target raised to $110 from $100 at SunTrust
09/26/19 UBS
Kinsale Capital Group price target raised to $112 from $98 at UBS
09/06/19 JMP Securities
Kinsale Capital Group initiated with a Market Perform at JMP Securities
HIGH Highland Financial
$0.00 /

+ (+0.00%)

OPK Opko Health
$5.91 /

+0.12 (+2.07%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
06/09/20 Piper Sandler
Opko Health price target raised to $4 from $3 at Piper Sandler
06/08/20 Piper Sandler
Opko Health, Pfizer data show IGF-1 normal at ENDO, says Piper Sandler
06/01/20 Piper Sandler
Piper keeps Overweight rating on Opko Health as FDA clears COVID-19 trial start
TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

07/20/20 Cleveland Research
Atlassian survey shows better than expected quarter, says Cleveland Research
07/20/20 Jefferies
Atlassian price target raised to $175 from $145 at Jefferies
07/14/20 Morgan Stanley
Atlassian price target raised to $200 from $173 at Morgan Stanley
07/01/20 KeyBanc
Atlassian price target raised to $201 from $163 at KeyBanc
CASA Casa Systems
$5.69 /

+0.89 (+18.54%)

04/14/20 JPMorgan
Casa Systems initiated with an Underweight at JPMorgan
02/12/20 Northland
Casa Systems upgraded to Outperform from Market Perform at Northland
11/01/19 Northland
Casa Systems downgraded to Market Perform from Outperform at Northland
08/07/19 Barclays
Casa Systems initiated with an Equal Weight at Barclays
WRTC Wrap Technologies
$11.54 /

+0.3 (+2.67%)

07/06/20 Northland
Wrap Technologies downgraded to Market Perform from Outperform at Northland
03/24/20 Northland
Wrap Technologies upgraded to Outperform from Market Perform at Northland
01/29/20 Ladenburg
Wrap Technologies initiated with a Buy at Ladenburg
01/29/20 Ladenburg
Wrap Technologies initiated with a Buy at Ladenburg
RDFN Redfin
$42.94 /

+1.4 (+3.37%)

07/28/20
Fly Intel: Top five analyst downgrades
07/28/20 Susquehanna
Redfin downgraded to Negative on valuation at Susquehanna
07/28/20 Susquehanna
Redfin downgraded to Negative from Neutral at Susquehanna
07/27/20 Zelman
Redfin upgraded to Buy from Hold at Zelman
TWOU 2U
$43.89 /

+0.62 (+1.43%)

07/28/20 Piper Sandler
2U price target raised to $49 from $42 at Piper Sandler
07/16/20 Jefferies
2U initiated with a Buy at Jefferies
06/29/20 KeyBanc
2U initiated with a Sector Weight at KeyBanc
06/16/20 Needham
Needham reiterates Buy on 2U after finding positive data point
SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

07/10/20 MKM Partners
Shake Shack price target lowered to $54 from $59 at MKM Partners
07/08/20 MKM Partners
Shake Shack's comps recovery continues at 'tempered pace', says MKM Partners
06/24/20 JPMorgan
Shake Shack price target raised to $51 from $47 at JPMorgan
05/06/20 Deutsche Bank
Shake Shack price target raised to $57 from $51 at Deutsche Bank
MOH Molina Healthcare
$188.74 /

+0.905 (+0.48%)

07/01/20 SVB Leerink
Molina Healthcare reinstated with an Outperform at SVB Leerink
06/16/20 Cowen
Cowen upgrades Molina Healthcare, organic growth and M&A potential seen
06/16/20 Cowen
Molina Healthcare upgraded to Outperform from Market Perform at Cowen
06/01/20 Truist
Molina Healthcare price target raised to $230 from $210 at SunTrust
EGHT 8x8, Inc.
$17.11 /

+0.01 (+0.06%)

06/09/20 Craig-Hallum
8x8, Inc. price target lowered to $18 from $22 at Craig-Hallum
05/13/20 Northland
8x8, Inc. price target lowered to $23 from $29 at Northland
05/13/20 B. Riley FBR
8x8, Inc. price target lowered to $12 from $13 at B. Riley FBR
05/13/20 Baird
8x8, Inc. price target lowered to $23 from $29 at Baird
POWI Power Integrations
$125.97 /

+2.84 (+2.31%)

07/28/20 Deutsche Bank
Power Integrations price target raised to $110 from $93 at Deutsche Bank
10/25/19
Loop Capital upgrades Power Integrations to Buy on accelerated product adoption
10/25/19 Loop Capital
Power Integrations upgraded to Buy from Hold at Loop Capital
EXPE Expedia
$84.94 /

-0.36 (-0.42%)

07/29/20 Jefferies
Booking Holdings price target raised to $1,600 from $1,300 at Jefferies
07/20/20 Goldman Sachs
Expedia price target raised to $65 from $60 at Goldman Sachs
07/15/20 Mizuho
Expedia price target raised to $85 from $80 at Mizuho
07/07/20 Truist
Expedia debt raise makes financial sense, says SunTrust
XPO XPO Logistics
$86.59 /

+2.475 (+2.94%)

07/17/20 Truist
SunTrust raises price targets in select Trucking/Logistics names
07/08/20 Citi
XPO Logistics price target raised to $92 from $73 at Citi
07/06/20 Barclays
XPO Logistics price target raised to $75 from $65 at Barclays
06/17/20 Deutsche Bank
XPO Logistics price target raised to $88 from $84 at Deutsche Bank
GILD Gilead
$72.30 /

-0.74 (-1.01%)

07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
07/20/20
Fly Intel: Top five analyst upgrades
07/20/20 Credit Suisse
Gilead upgraded to Neutral from Underperform at Credit Suisse
07/14/20 Benchmark
Ligand price target raised to $155 from $135 at Benchmark
FORM FormFactor
$30.87 /

+0.78 (+2.59%)

07/20/20 Citi
FormFactor upgraded to Buy from Neutral at Citi
07/08/20 B. Riley FBR
FormFactor price target raised to $40 from $36 at B. Riley FBR
07/02/20
Fly Intel: Top five analyst downgrades
07/02/20 Craig-Hallum
FormFactor downgraded to Hold at Craig-Hallum
XLNX Xilinx
$111.94 /

+4.06 (+3.76%)

07/17/20 Deutsche Bank
Xilinx price target raised to $100 from $90 at Deutsche Bank
07/06/20 Rosenblatt
Samsung on track to replace Nokia as 5G RAN supplier at Verizon, says Rosenblatt
07/06/20 Goldman Sachs
Xilinx upgraded to Conviction Buy from Buy at Goldman Sachs
06/30/20 Truist
Xilinx price target raised to $104 from $93 at SunTrust
MITK Mitek Systems
$10.82 /

+0.83 (+8.31%)

03/25/20 National Securities
Mitek Systems upgraded to Buy from Neutral at National Securities
01/06/20 Benchmark
Benchmark names Alibaba, Nvidia, Comcast among best ideas for first half
11/15/19
Fly Intel: Top five analyst downgrades
11/15/19 Roth Capital
Mitek Systems downgraded on USAA litigation risk at Roth Capital
NVST Envista
$22.59 /

-0.15 (-0.66%)

06/16/20
Fly Intel: Top five analyst initiations
06/16/20 Piper Sandler
Envista initiated with a Neutral at Piper Sandler
01/15/20 Jefferies
SmileDirect traditional channel entry makes competitive 'noise,' says Jefferies
12/19/19 JPMorgan
Danaher price target raised to $175 from $155 at JPMorgan
ZEN Zendesk
$100.46 /

+1.16 (+1.17%)

07/30/20 Wells Fargo
Zendesk price target raised to $120 from $95 at Wells Fargo
07/21/20 RBC Capital
Zendesk price target raised to $120 from $100 at RBC Capital
07/16/20 Citi
Zendesk initiated with a Neutral at Citi
06/29/20 Goldman Sachs
Zendesk price target raised to $113 from $96 at Goldman Sachs
TDW Tidewater
$6.17 /

-0.21 (-3.29%)

03/09/20 Evercore ISI
Tidewater downgraded to In Line from Outperform at Evercore ISI
SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

07/24/20 Piper Sandler
Seattle Genetics downgraded to Neutral from Overweight at Piper Sandler
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
FND Floor & Decor
$70.00 /

-0.57 (-0.81%)

07/27/20 Baird
Floor & Decor price target raised to $75 from $60 at Baird
07/22/20 Wells Fargo
Floor & Decor price target raised to $70 from $48 at Wells Fargo
06/24/20 Wedbush
Floor & Decor price target raised to $65 from $60 at Wedbush
06/24/20 Berenberg
Berenberg starts 'low-cost leader' Floor & Decor at Buy
ZEN Zendesk
$100.46 /

+1.16 (+1.17%)

XPO XPO Logistics
$86.59 /

+2.475 (+2.94%)

XLNX Xilinx
$111.94 /

+4.06 (+3.76%)

WWE WWE
$45.45 /

+0.85 (+1.91%)

WRTC Wrap Technologies
$11.54 /

+0.3 (+2.67%)

VRTU Virtusa
$35.18 /

+0.4 (+1.15%)

TWOU 2U
$43.89 /

+0.62 (+1.43%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

TDW Tidewater
$6.17 /

-0.21 (-3.29%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

RP RealPage
$62.86 /

-0.26 (-0.41%)

RDFN Redfin
$42.94 /

+1.4 (+3.37%)

POWI Power Integrations
$125.97 /

+2.84 (+2.31%)

OPK Opko Health
$5.91 /

+0.12 (+2.07%)

NVST Envista
$22.59 /

-0.15 (-0.66%)

MX MagnaChip
$11.33 /

+0.4 (+3.66%)

MOH Molina Healthcare
$188.74 /

+0.905 (+0.48%)

MITK Mitek Systems
$10.82 /

+0.83 (+8.31%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

LOCO El Pollo Loco
$17.21 /

+0.17 (+1.00%)

KNSL Kinsale Capital Group
$166.09 /

-0.84 (-0.50%)

HURN Huron
$44.15 /

+0.32 (+0.73%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FORM FormFactor
$30.87 /

+0.78 (+2.59%)

FND Floor & Decor
$70.00 /

-0.57 (-0.81%)

FLS Flowserve
$29.93 /

-0.51 (-1.68%)

FLEX Flex
$11.64 /

+0.575 (+5.20%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

F Ford
$6.74 /

-0.18 (-2.60%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

EGHT 8x8, Inc.
$17.11 /

+0.01 (+0.06%)

CVA Covanta
$9.53 /

-0.13 (-1.35%)

CASA Casa Systems
$5.69 /

+0.89 (+18.54%)

BZH Beazer Homes
$11.29 /

-0.095 (-0.83%)

BRKS Brooks Automation
$47.22 /

+1.16 (+2.52%)

BLDR Builders FirstSource
$23.38 /

-0.33 (-1.39%)

BAND Bandwidth
$148.70 /

+1.51 (+1.03%)

ATUS Altice USA
$25.09 /

-0.135 (-0.54%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

  • 23
    Jun
  • 20
    May
  • 20
    May
  • 06
    May
  • 25
    Mar
  • 15
    Nov
  • 25
    Oct
  • 11
    Sep
  • 18
    Sep
  • 16
    Aug
  • 08
    Aug
WWE WWE
$45.45 /

+0.85 (+1.91%)

WRTC Wrap Technologies
$11.54 /

+0.3 (+2.67%)

TWOU 2U
$43.89 /

+0.62 (+1.43%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

OPK Opko Health
$5.91 /

+0.12 (+2.07%)

MOH Molina Healthcare
$188.74 /

+0.905 (+0.48%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FLS Flowserve
$29.93 /

-0.51 (-1.68%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

F Ford
$6.74 /

-0.18 (-2.60%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

EGHT 8x8, Inc.
$17.11 /

+0.01 (+0.06%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

XPO XPO Logistics
$86.59 /

+2.475 (+2.94%)

XLNX Xilinx
$111.94 /

+4.06 (+3.76%)

WWE WWE
$45.45 /

+0.85 (+1.91%)

VRTU Virtusa
$35.18 /

+0.4 (+1.15%)

TWOU 2U
$43.89 /

+0.62 (+1.43%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

SGEN Seattle Genetics
$171.04 /

+2.62 (+1.56%)

RP RealPage
$62.86 /

-0.26 (-0.41%)

RDFN Redfin
$42.94 /

+1.4 (+3.37%)

OPK Opko Health
$5.91 /

+0.12 (+2.07%)

MX MagnaChip
$11.33 /

+0.4 (+3.66%)

MOH Molina Healthcare
$188.74 /

+0.905 (+0.48%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FORM FormFactor
$30.87 /

+0.78 (+2.59%)

FND Floor & Decor
$70.00 /

-0.57 (-0.81%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

F Ford
$6.74 /

-0.18 (-2.60%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

EGHT 8x8, Inc.
$17.11 /

+0.01 (+0.06%)

CVA Covanta
$9.53 /

-0.13 (-1.35%)

BZH Beazer Homes
$11.29 /

-0.095 (-0.83%)

BLDR Builders FirstSource
$23.38 /

-0.33 (-1.39%)

ATUS Altice USA
$25.09 /

-0.135 (-0.54%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

XPO XPO Logistics
$86.59 /

+2.475 (+2.94%)

XLNX Xilinx
$111.94 /

+4.06 (+3.76%)

WWE WWE
$45.45 /

+0.85 (+1.91%)

WRTC Wrap Technologies
$11.54 /

+0.3 (+2.67%)

TWOU 2U
$43.89 /

+0.62 (+1.43%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

RDFN Redfin
$42.94 /

+1.4 (+3.37%)

OPK Opko Health
$5.91 /

+0.12 (+2.07%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FLS Flowserve
$29.93 /

-0.51 (-1.68%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

F Ford
$6.74 /

-0.18 (-2.60%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

EGHT 8x8, Inc.
$17.11 /

+0.01 (+0.06%)

ATUS Altice USA
$25.09 /

-0.135 (-0.54%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

Hot Stocks
Seattle Genetics sees FY20 Adcetris net product sales $675M-$700M » 16:04
07/30/20
07/30
16:04
07/30/20
16:04
SGEN

Seattle Genetics

$171.45 /

+3.03 (+1.80%)

Sees FY20 Padcev net…

Sees FY20 Padcev net product sales $215M-$235M. Sees FY20 royalty revenues $105M-$115M.

ShowHide Related Items >><<
SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

07/24/20 Piper Sandler
Seattle Genetics downgraded to Neutral from Overweight at Piper Sandler
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

Earnings
Seattle Genetics reports Q2 EPS (12c), consensus (63c) » 16:03
07/30/20
07/30
16:03
07/30/20
16:03
SGEN

Seattle Genetics

$171.45 /

+3.03 (+1.80%)

Reports Q2 revenue $278M,…

Reports Q2 revenue $278M, consensus $256.43M. "We generated record product sales of $240.5 million in the second quarter driven by ADCETRIS, PADCEV and now a third commercial product, TUKYSA, following the FDA approval in mid-April for metastatic HER2-positive breast cancer," said Clay Siegall, Ph.D., President and CEO of Seattle Genetics. "We successfully launched TUKYSA in the United States and are building our international capabilities to support global launches. In addition, we reported another quarter of strong PADCEV sales with revenues of $91.6 million in its first two full quarters on the market. Our total revenues are on track to exceed $1 billion in 2020."

ShowHide Related Items >><<
SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

07/24/20 Piper Sandler
Seattle Genetics downgraded to Neutral from Overweight at Piper Sandler
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

SGEN Seattle Genetics
$171.45 /

+3.03 (+1.80%)

Downgrade
Seattle Genetics downgraded to Neutral from Overweight at Piper Sandler » 05:00
07/24/20
07/24
05:00
07/24/20
05:00
SGEN

Seattle Genetics

$172.96 /

-3.79 (-2.14%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro downgraded Seattle Genetics to Neutral from Overweight with a price target of $165, up from $155. The stock closed Thursday down $3.93 to $172.90. Over the next 12 months, the analyst sees limited visibility into "significant value creating events" like the last year provided, particularly at the current valuation. Further, most recent key opinion leader checks suggest Q2 Padcev revenues may not provide the upside that Q1 did, Catanzaro tells investors in a research note. Seattle Genetics' execution over last 12 months has been solid, but the shares offer limited upside from here, says the analyst.

ShowHide Related Items >><<
SGEN Seattle Genetics
$172.96 /

-3.79 (-2.14%)

SGEN Seattle Genetics
$172.96 /

-3.79 (-2.14%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
SGEN Seattle Genetics
$172.96 /

-3.79 (-2.14%)

SGEN Seattle Genetics
$172.96 /

-3.79 (-2.14%)

Over a month ago
Hot Stocks
Xoma appoints Natasha Hernday to board of directors » 07:57
07/01/20
07/01
07:57
07/01/20
07:57
XOMA

Xoma

$19.79 /

-2.04 (-9.34%)

, SGEN

Seattle Genetics

$169.95 /

+5.54 (+3.37%)

XOMA Corporation (XOMA)…

XOMA Corporation (XOMA) announced Natasha Hernday, SVP, Corporate Development at Seattle Genetics (SGEN), has joined the Company's Board of Directors.

ShowHide Related Items >><<
XOMA Xoma
$19.79 /

-2.04 (-9.34%)

SGEN Seattle Genetics
$169.95 /

+5.54 (+3.37%)

XOMA Xoma
$19.79 /

-2.04 (-9.34%)

03/10/20 H.C. Wainwright
Novartis' recent R&D day driving interest in Xoma, says H.C. Wainwright
SGEN Seattle Genetics
$169.95 /

+5.54 (+3.37%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
XOMA Xoma
$19.79 /

-2.04 (-9.34%)

SGEN Seattle Genetics
$169.95 /

+5.54 (+3.37%)

  • 24
    Jul
SGEN Seattle Genetics
$169.95 /

+5.54 (+3.37%)

Recommendations
Seattle Genetics price target raised to $167 from $155 at SVB Leerink » 09:24
06/30/20
06/30
09:24
06/30/20
09:24
SGEN

Seattle Genetics

$164.41 /

-1.33 (-0.80%)

, GMAB

Genmab

$32.60 /

+0.57 (+1.78%)

, MRK

Merck

$76.07 /

+0.9 (+1.20%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens raised the firm's price target on Seattle Genetics (SGEN) to $167 from $155 and keeps an Outperform rating on the shares. The analyst notes that Seattle Genetics and its partner Genmab (GMAB) announced top-line results from the innovaTV 204 Phase 2 study evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer who have progressed after prior treatment. Berens believes most investors were looking for monotherapy data that could support an accelerated pathway, which this top-line release suggests is probable, given limited treatment options in these patients and the relatively low bar for efficacy. While detailed data are yet to be presented at an upcoming medical meeting in 2020, he is "encouraged" by the data, which suggest that TV could become the fourth commercial asset in Seattle Genetics' portfolio. Importantly, Berens thinks TV could be combined with Merck's (MRK) Keytruda as a key strategy going forward, which would expand Keytruda's therapeutic reach beyond its currently approved label for PD-L1+ cervical cancer patients.

ShowHide Related Items >><<
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

06/30/20 BMO Capital
Seattle Genetics price target raised to $186 from $174 at BMO Capital
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
06/26/20 Oppenheimer
Seattle Genetics price target raised to $200 from $175 at Oppenheimer
GMAB Genmab
$32.60 /

+0.57 (+1.78%)

06/25/20 Credit Suisse
Genmab downgraded to Neutral from Outperform at Credit Suisse
06/19/20 RBC Capital
Genmab price target raised to $35 from $27 at RBC Capital
06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
MRK Merck
$76.07 /

+0.9 (+1.20%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

  • 24
    Jul
  • 18
    Jul
MRK Merck
$76.07 /

+0.9 (+1.20%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

GMAB Genmab
$32.60 /

+0.57 (+1.78%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

Recommendations
Seattle Genetics price target raised to $186 from $174 at BMO Capital » 08:56
06/30/20
06/30
08:56
06/30/20
08:56
SGEN

Seattle Genetics

$164.41 /

-1.33 (-0.80%)

BMO Capital analyst…

BMO Capital analyst George Farmer raised the firm's price target on Seattle Genetics to $186 from $174 and keeps an Outperform rating on the shares after the company's announced "success of the Phase 2 registration trial evaluating tisotumab vedotin for treatment of advanced cervical cancer." The analyst is still assuming a "modest" penetration rate of about 33% and global peak sales of about $423M in the program. Farmer is also raising his FY21 EPS view to (41c) from (50c) and also sees continued share momentum driven by near-term growth of Seattle Genetics' newly marketed products, Padcev and Tukysa.

ShowHide Related Items >><<
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
06/26/20 Oppenheimer
Seattle Genetics price target raised to $200 from $175 at Oppenheimer
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

  • 24
    Jul
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

Recommendations
Seattle Genetics price target raised to $210 from $200 at Oppenheimer » 07:42
06/30/20
06/30
07:42
06/30/20
07:42
SGEN

Seattle Genetics

$164.41 /

-1.33 (-0.80%)

, MRK

Merck

$76.07 /

+0.9 (+1.20%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson raised the firm's price target on Seattle Genetics (SGEN) to $210 from $200 and keeps an Outperform rating on the shares. The analyst notes that the company announced positive top-line results from the Phase 2 study of Tisotumab Vedotin in cervical cancer. Olson views Tisotumab Vedotin top-line efficacy as likely approvable based on a favorable comparison to Merck's (MRK) Keytruda and anticipates an accelerated approval pathway. Based on top-line results, he increased his Probability of Success estimate for Tisotumab Vedotin to 90%.

ShowHide Related Items >><<
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

06/30/20 Guggenheim
Guggenheim says Seattle Genetics' cervical cancer data 'a positive surprise'
06/26/20 Oppenheimer
Seattle Genetics price target raised to $200 from $175 at Oppenheimer
06/10/20 Guggenheim
Merck's bladder cancer failure boosts strategic value of Padcev, says Guggenheim
06/01/20 Oppenheimer
Seattle Genetics price target raised to $175 from $146 at Oppenheimer
MRK Merck
$76.07 /

+0.9 (+1.20%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

  • 24
    Jul
MRK Merck
$76.07 /

+0.9 (+1.20%)

SGEN Seattle Genetics
$164.41 /

-1.33 (-0.80%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

MRK Merck
$76.07 /

+0.9 (+1.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.